Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IMATINIB Cause Peripheral arterial occlusive disease? 86 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 86 reports of Peripheral arterial occlusive disease have been filed in association with IMATINIB (Imatinib). This represents 0.2% of all adverse event reports for IMATINIB.

86
Reports of Peripheral arterial occlusive disease with IMATINIB
0.2%
of all IMATINIB reports
9
Deaths
14
Hospitalizations

How Dangerous Is Peripheral arterial occlusive disease From IMATINIB?

Of the 86 reports, 9 (10.5%) resulted in death, 14 (16.3%) required hospitalization, and 4 (4.7%) were considered life-threatening.

Is Peripheral arterial occlusive disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IMATINIB. However, 86 reports have been filed with the FAERS database.

What Other Side Effects Does IMATINIB Cause?

Death (9,708) Drug ineffective (2,628) Nausea (2,379) Diarrhoea (2,203) Fatigue (1,810) Malignant neoplasm progression (1,716) Vomiting (1,599) Malaise (1,361) Drug intolerance (1,354) Drug resistance (1,293)

What Other Drugs Cause Peripheral arterial occlusive disease?

NILOTINIB (319) METHOTREXATE (120) ADALIMUMAB (116) RIVAROXABAN (101) PONATINIB (90) ASPIRIN (77) ATORVASTATIN (70) METOPROLOL (70) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (63) ETELCALCETIDE (63)

Which IMATINIB Alternatives Have Lower Peripheral arterial occlusive disease Risk?

IMATINIB vs IMBRUVICA IMATINIB vs IMDEVIMAB IMATINIB vs IMEGLIMIN IMATINIB vs IMETELSTAT IMATINIB vs IMIDAPRIL

Related Pages

IMATINIB Full Profile All Peripheral arterial occlusive disease Reports All Drugs Causing Peripheral arterial occlusive disease IMATINIB Demographics